On This Page – Quick Medical Summary
If you have sickle cell trait and just got an A1C result
If you carry sickle cell trait and you are looking at an A1C number, you have a reasonable question that most pages answer badly. The short version: your trait can matter, but not in the way the internet usually says.
Find yourself below.
- You have the trait and a result in hand. Start with the section on whether the test is accurate, then read the one on normal results.
- You have the trait and are already living with diabetes. The section on the measured difference between groups is written for you.
- You saw “variant hemoglobin” on a report and want to know what it means. Skip to what an A1C can and cannot say about the trait itself.
- You are not sure whether you carry the trait. That uncertainty is common, and the three actions section starts there.
- You have sickle cell disease, not the trait. This page is not written for you. Sickle cell disease changes this test in a different and more fundamental way, and your answer should come from the team that manages your care.
If your number sits near a diagnostic boundary and you want the general picture first, our A1C ranges chart and the full guide to reading an A1C result cover what the test measures for everyone. The CDC’s factsheet for people with sickle cell trait confirms this is a recognized issue with published federal guidance behind it, not an internet worry.
ℹ️ Medical Disclaimer: This article is general health education about a laboratory test. It does not diagnose diabetes, prediabetes, sickle cell trait or any other condition; it does not recommend, start, stop or adjust any medication or treatment; and it does not tell you which tests to order or decline. Decisions about diagnosis, testing, monitoring and treatment belong to you and a licensed clinician who can see your full history — usually your primary care physician, and in some cases a hematologist. If you are unwell now, contact your clinician or emergency services rather than reading further.
Sickle cell trait is not sickle cell disease
Almost every confusing thing written about this topic comes from one mix-up, so it is worth clearing first.
One gene, one usual gene, and what that leaves in your blood
Sickle cell disease happens when a person inherits the sickle hemoglobin gene from both parents. Sickle cell trait means inheriting it from one parent and the usual hemoglobin gene from the other. The CDC describes people with the trait as usually having none of the symptoms of the disease, and notes that when both parents carry the trait, each pregnancy carries a 1 in 2 chance of the trait and a 1 in 4 chance of the disease.
The NIDDK uses the clinical words for the same idea: someone with two copies is homozygous, someone with one copy is heterozygous and may be called a carrier, and people in that second group are usually asymptomatic. You can read the plain-language version of how sickle cell trait is inherited on the CDC’s page.
🔬 How It Works: The A1C test does not measure sugar directly. It measures how much glucose has attached to hemoglobin A — the ordinary adult hemoglobin — inside your red blood cells. If you have sickle cell trait, one of your two genes is still the usual one, so you still produce hemoglobin A in quantity. There is something for the test to measure, and that is the whole reason the trait and the disease are different problems here.
Why sickle cell disease is a different question for this test
The current American Diabetes Association Standards of Care, published for 2026, states the contrast in the sharpest possible terms: A1C cannot be measured in people with sickle cell disease or other homozygous hemoglobin variants, because those individuals lack hemoglobin A altogether. The NIDDK gives clinicians the matching instruction — do not use the A1C test in those patients.
That is not a harder version of the trait problem. It is a different one. Everything below concerns the trait.
Does sickle cell trait make the A1C test inaccurate?
Usually not, on the methods most American laboratories run today — and the qualifications on that sentence matter more than the sentence.
What the current guidance says about trait and A1C accuracy
The NIDDK’s page on hemoglobin variants and diabetes puts it plainly: manufacturers have reduced analytic interference from hemoglobin variants, so A1C can be measured accurately in the presence of most variants provided a suitable assay is used. The 2026 ADA Standards say the same thing in guideline language — most assays in use in the United States are accurate in people who are heterozygous for the most common variants, which is exactly the group this article is about. The Standards also say that where a variant is known, a method without interference from it should be used.
You can read the federal summary of how hemoglobin variants affect A1C testing in full. Both that page and the ADA point clinicians to the same place for method-by-method detail: the National Glycohemoglobin Standardization Program, or NGSP.
What “no interference” is actually measured against
Here is the part nobody prints: the NGSP’s interference table, updated in June 2026, does not claim that a listed method is unaffected by sickle cell trait. It states its own threshold — a method is marked as showing interference when the effect exceeds roughly 6% at an A1C of 6% and 9%. “No” on that table therefore means below a defined tolerance, not no effect at all.
Across the twenty most-used methods on that table, all but one are marked as showing no clinically significant interference from sickle cell trait, and the single exception carries a footnote saying the published data conflict.
Where the exceptions cluster
The NGSP publishes a second, fuller table, updated 23 June 2026, covering roughly twice as many methods, and it states openly that the criteria for interference vary depending on the data source — so the two tables answer slightly different questions rather than disagreeing. On that longer list, several methods are recorded as showing interference from sickle cell trait, and they are disproportionately devices built for use outside a central laboratory. One instrument even appears twice with opposite answers depending on which software mode the lab runs.
| What you are looking at | What it covers | Key clinical detail |
|---|---|---|
| “No interference” on a method list | One method, one variant | A tolerance judgment, not zero effect — the threshold is stated on the table itself |
| The 20-method table (June 2026) | The methods most laboratories run | All but one show no clinically significant interference from sickle cell trait |
| The fuller table (23 June 2026) | Roughly twice as many methods | Criteria vary by data source; several methods do show interference, and they skew toward devices used outside a laboratory |
Source: National Glycohemoglobin Standardization Program interference tables, as published June 2026. The two tables answer different questions; neither corrects the other.
🩺 Physician Note: Current guidance treats the assay method as a known, checkable variable rather than an unknown. That is why both the ADA Standards and the CDC’s provider factsheet point to a public list of methods instead of advising clinicians to distrust the test. If you want the general picture of how any A1C is held to a standard, our guide to how labs prove an A1C is accurate covers the certification and quality system behind every result.
The small difference researchers keep measuring
There is a second question hiding behind the first, and it is not about laboratory equipment at all.
What a large study found in people with the trait
In 2017, researchers publishing in JAMA compared A1C results against directly measured blood sugar in 4,620 African American adults drawn from two long-running community studies, 367 of whom had sickle cell trait. At the same fasting glucose level, A1C averaged about 0.3 percentage points lower in the group with the trait. The same gap appeared when they used a two-hour glucose measurement instead, and it was larger at higher blood sugar levels.
📊 Clinical Data Point: When prediabetes was defined using A1C, its measured prevalence was 29.2% in the group with sickle cell trait and 48.6% in the group without it; for diabetes the figures were 3.8% and 7.3%. These describe how an A1C-based definition behaved across two groups of people — they are not a statement about any one reader’s risk. Source: Lacy ME et al., JAMA, 2017;317(5):507–515, doi:10.1001/jama.2016.21035.
Why nobody can yet say exactly what causes it
The honest position is that the association has been measured and the mechanism has not been settled for the trait.
The NGSP does state that conditions shortening red blood cell survival lower A1C regardless of method — but the examples it gives are recent blood loss and hemolytic anemia, and its warning about interpreting results applies to sickle cell disease and other two-gene states. No source in this article supports the claim, repeated across much of the web, that sickle cell trait itself shortens red cell survival. Other red-cell conditions do change A1C through routes of their own, which is why anemia and low hemoglobin are handled separately.
Why you should not add anything to your own result
A difference of about 0.3 points across thousands of people is not a correction factor for one person: nobody knows how much of that average belongs to you, and adjusting your own number would replace a measured result with a guess. The study’s authors suggested clinicians consider additional blood sugar measurements for patients whose results sit close to a decision point — a clinical judgment, not patient arithmetic. If your result sits in the borderline range, what doctors check after a borderline result covers what usually happens next.
Why a normal A1C may not settle the question
This is the part of the topic that gets least attention and deserves most.
What a reassuring number can and cannot rule out
The CDC’s guidance for healthcare providers on sickle cell trait and A1C contains one sentence that reframes everything above it: for people with sickle cell trait, a normal A1C might not provide assurance that diabetes is absent.
Read that carefully: it does not say a normal result is wrong, it says a normal result answers less here than it usually does — which makes it the result most worth a second look, not the least. The CDC’s patient factsheet states the risk in both directions in a single sentence: false results could lead to being undertreated or overtreated for diabetes. Our guide to what a normal A1C level means sets out what that number settles for most people.
⚠️ Clinical Warning: Do not use this page as a reason to dismiss an elevated A1C, and do not use it as a reason to relax about a normal one. Both errors have been documented. A result that does not fit how you feel, or does not fit your home glucose readings, is a reason to raise the question with a clinician — not a reason to decide the answer yourself.
What the current guidance says to use instead
The 2026 ADA Standards address this directly. Recommendation 2.4 says that where the relationship between A1C and blood sugar is altered — and it names hemoglobin variants among those situations — plasma glucose criteria should be used to diagnose diabetes. Recommendation 2.3 adds that a consistent, substantial mismatch between blood sugar readings and A1C results should itself prompt a look at whether something is interfering.
That is also why a single result rarely stands alone; our guide to why a diagnosis needs a second test and the detail on confirmatory A1C testing explain the general rule.
✅ Patient Action: At your next appointment with your primary care physician, ask this specific question: “I have sickle cell trait — should we add a fasting glucose or an oral glucose tolerance test rather than relying on the A1C alone?”
Three things to do before your next A1C test
These work in order. The first is the one most people skip.
Confirm whether you actually carry the trait
Many people who carry a hemoglobin variant have never been told, because it usually causes no symptoms — the NIDDK makes this point explicitly about people with one variant gene. The CDC’s answer is short: sickle cell trait is diagnosed with a simple blood test, and people who may be at risk can raise it with a doctor or clinic. The laboratory methods that identify it are hemoglobin electrophoresis, high-performance liquid chromatography, or isoelectric focusing.
Tell whoever orders the test
The CDC’s patient factsheet asks you to make sure your doctor knows your trait status and knows it might affect your A1C results, so they can either use other tests or arrange for the A1C to be run by a method that gives accurate results. That is a two-sentence conversation that changes what the laboratory does.
Ask which method the laboratory uses — and about a glucose test
The NGSP’s own advice to doctors and patients is to find out which method the laboratory is using before asking whether it is accurate for a variant. Both the CDC’s provider guidance and the 2026 ADA Standards send readers to that same list, which is why it is worth naming.
Three patterns are treated as reasons to suspect a hemoglobin variant is affecting a result: an A1C that is unexpected or at odds with other diabetes test results; home glucose readings that disagree with the A1C; and an A1C that changed sharply right after the laboratory changed its method. That last one is the least known and the easiest to check on your own records. If your readings and your A1C disagree, how A1C compares with fasting glucose explains what each measures, and our blood sugar converter will move a glucose result between mg/dL and mmol/L.
✅ Patient Action: Before your next test, ask the clinician who orders it: “Does the lab you use run an A1C method that is unaffected by sickle cell trait — and if you are not sure, can we add a fasting glucose this time?”
What an A1C can and cannot say about the trait itself
Some readers arrive here from the opposite direction: not “how does my trait affect this test,” but “did this test just tell me something about my trait?”
Can an A1C test diagnose sickle cell trait?
No — the A1C test is not designed to look for sickle cell trait. The CDC’s provider guidance is explicit: some A1C methods might detect a variant hemoglobin, which in some cases could be sickle hemoglobin, but that result should not be treated as a diagnostic test for the trait. Sickle cell trait is confirmed only with a test approved for hemoglobin identification.
What a “variant hemoglobin” note on a report does and does not mean
It means the instrument saw something it could not fit into its usual pattern; it does not name which variant, and it is not a carrier result. The correct next step is a hemoglobin identification test, not a repeat A1C. The NHLBI’s sickle cell trait fact sheet, published in March 2025, covers who is affected and how to find out whether you carry it.
Why we do not recommend an at-home A1C kit for this
We are not recommending or linking any at-home or pharmacy fingerstick A1C product on this page, and the reason comes from our own cited sources rather than from caution.
The 2026 ADA Standards restrict point-of-care A1C testing for screening and diagnosis to devices approved for that purpose, and the CDC’s factsheet asks your doctor to arrange a method appropriate for your trait — something a direct purchase cannot do. On the NGSP’s fuller table, the methods recorded as showing interference from sickle cell trait include devices built for use outside a laboratory — and for a general comparison of the two settings, see how at-home blood tests compare with a lab. A mail-in kit processed by a certified laboratory is a different arrangement from a fingerstick device read at home, and the two should not be treated as one.
✅ Patient Action: If you have never had your hemoglobin formally typed, ask your primary care physician: “Has my hemoglobin ever actually been tested, or is my trait status something I was told without a test?”
Common questions about sickle cell trait and A1C
1. Does sickle cell trait affect A1C results?
It can, depending on the method your laboratory uses. Current federal guidance says A1C can be measured accurately in the presence of most hemoglobin variants when a suitable assay is used, and the 2026 ADA Standards say most assays used in the United States are accurate for people carrying one copy of a common variant. Where a method does interfere with sickle cell trait, results may read high or low.
2. Is sickle cell trait the same as sickle cell disease?
No — sickle cell trait means one sickle gene and one usual gene, while sickle cell disease means two sickle genes. People with the trait usually have none of the symptoms of the disease. The distinction matters for this test because people with the trait still make ordinary hemoglobin A, which is what the A1C measures, and people with sickle cell disease do not.
3. Can an A1C test detect sickle cell trait?
No — the A1C test is not designed to find sickle cell trait, though some methods may flag a variant hemoglobin, which in some cases could be sickle hemoglobin, but the CDC states that such a result should not be treated as a diagnosis. Sickle cell trait is confirmed only with a test approved for hemoglobin identification, and that is a separate blood test.
4. Why would my A1C be falsely low with sickle cell trait?
Two separate things can lower a result. Some laboratory assay methods interfere with sickle cell trait and can read low; separately, research has measured A1C running roughly 0.3 percentage points lower on average in people with the trait at the same blood sugar level, and the cause of that difference is not settled. Discuss any result that surprises you with your clinician.
5. Can I trust a normal A1C if I have sickle cell trait?
Treat it as informative but not final: the CDC’s provider guidance states that for people with sickle cell trait a normal A1C might not provide assurance that diabetes is absent. That makes a normal result worth confirming rather than worth ignoring, particularly if your home glucose readings or symptoms do not match it. Raise any mismatch with your clinician.
6. What test should I have instead of an A1C?
The 2026 ADA Standards say that where a hemoglobin variant alters the relationship between A1C and blood sugar, plasma glucose criteria should be used to diagnose diabetes — a fasting glucose or an oral glucose tolerance test. In most cases with sickle cell trait this is an addition rather than a replacement. Which applies to you is a decision for your clinician.
7. How do I find out which A1C method my lab uses?
The NGSP’s advice to patients and doctors is to establish which method the laboratory is using before asking whether it is accurate for a variant. In practice that means asking the clinician who orders your test, or the laboratory itself, and the answer is a method name. Both the CDC’s provider guidance and the 2026 ADA Standards direct readers to the same published list of methods.
8. How do I find out if I have sickle cell trait?
The CDC says sickle cell trait is diagnosed with a simple blood test, and that people who may be at risk can ask a doctor or clinic about it. The laboratory techniques used to identify it are hemoglobin electrophoresis, high-performance liquid chromatography, or isoelectric focusing. Many people with sickle cell trait have never been told, because it usually causes no symptoms at all.
9. Do home A1C tests work if you have sickle cell trait?
We do not recommend one here. The 2026 ADA Standards restrict point-of-care A1C testing for screening and diagnosis to devices approved for that purpose, and on the NGSP’s fuller table the methods recorded as interfering with sickle cell trait include devices designed for use outside a laboratory. A mail-in kit processed by a certified lab is a different arrangement from a fingerstick device.
10. Should I add 0.3 to my A1C if I have sickle cell trait?
No — that figure is an average difference measured across thousands of people, not a correction for an individual, and nobody can say how much of it applies to you. Adjusting your own number replaces a measured result with a guess. If your result sits near a decision point, the useful step is asking your clinician about adding a blood glucose test.
11. Does sickle cell trait change how often I should be screened for diabetes?
No published guidance sets a different screening interval for people with sickle cell trait. What current guidance changes is which test is used: where a hemoglobin variant alters the relationship between A1C and blood sugar, the 2026 ADA Standards point to plasma glucose criteria for diagnosis. Your screening schedule remains a conversation with your clinician.
What to take from this, and what to ask next
Two things are true at once, and holding both is the whole answer. On the methods most American laboratories run today, sickle cell trait usually does not distort an A1C — and a normal A1C still says less for you than it would for someone without the trait.
Neither of those facts is a reason to distrust the test or to stop having it. They are reasons to make one extra thing explicit at your next appointment.
Three questions cover it:
- Has my hemoglobin ever actually been tested, or was I told about the trait without one?
- Does the laboratory you use run an A1C method that is unaffected by sickle cell trait?
- Should we add a fasting glucose or an oral glucose tolerance test alongside the A1C?
For everything the test measures and how far one number can be trusted in general, our full A1C explainer is the place to start.
About this content
How this article was put together: researched from recognised health sources, drafted with the help of AI tools, and edited by hand, with sources linked throughout.
Sameer Patel is the founder and editor of My Medicine Advisor. He is not a doctor or medical professional — before starting this site he worked in banking,…
Medical disclaimer
The content on MyMedicineAdvisor is provided for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Health information on this website should not be used to diagnose, treat, cure, or prevent any condition without guidance from a qualified healthcare professional. Always seek the advice of your doctor, physician, or another licensed healthcare provider with any questions you may have regarding a medical condition, symptoms, medications, or treatment decisions.
